Relapsed/Refractory B-cell Malignancies
16
8
8
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
15 treatments under study, led by Ubx303061
Research Leaders
16 sponsors active, led by Nanjing Legend Biotech Co.
Related Conditions
Often studied with 17 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 16 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (16)
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies
Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.
Research Network
Common Treatments
- Ubx3030611
- Lvivotavec122 Product1
- Cd19 Chimeric Antigen Receptor Car T Cells1
- Zzsw01 Injection1
- Mdx20031
Active Sponsors
- Nanjing Legend Biotech Co.3
- The First Affiliated Hospital with Nanjing Medical University3
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2
- Haisco Pharmaceutical Group Co., Ltd.1
- Gilead Sciences1
Top Investigators
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The First Affiliated Hospital with Nanjing Medical University
79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China
Haisco Pharmaceutical Group Co., Ltd.
Related Conditions
- Follicular Lymphoma Fl2
- Primary Central Nervous System Lymphoma Pcnsl1
- Chronic Lymphocytic Leukemia Cll1
- Dlbcl Diffuse Large B Cell Lymphoma1
- Secondary Central Nervous System Lymphoma Scnsl1